BSEM — BioStem Technologies Share News
0.000.00%
Last trade - 00:00- $29.32m
- $23.35m
- $47.48m
BioStem Technologies, Inc. reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
BioStem Technologies Q1 revenue falls 62% yr/yr
BioStem Q3 revenue falls 43%, net income sinks
Brief: Biostem Technologies Completes Enrollment In Clinical Trial Evaluating Bioretain® Amnion Chorion For Treatment Of Diabetic Foot Ulcers
Brief: BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
Brief: Biostem Technologies Appoints Executive Leader Patrick Daly To Board Of Directors
Brief: Novabay Pharmaceuticals Announces Agreement With Biostem Technologies To Commercialize Amniotic Tissue Allograft
Brief: Biostem Technologies To Acquire Majority Of Assets Of Auxocell Laboratories, Inc.
Brief: Biostem Promotes Michael Fortunato, CPA To Chief Financial Officer
Brief: Biostem Technologies Appoints Medtech Financial Leader Brandon Poe to its board of directors
Brief: Biostem Technologies Reports Second Quarter 2022 Operating And Financial Results